Biotech Values

[bridgeofsighs]

Byetta was up against a double edge sword today panel meeting goes well and there is new competition. The panel meeting goes poorly and LAR could be slowed down. IMHO I thought the meeting went well for AMLN. Byetta in animal studies had no issues with tumors in normal dosing. The endocrinologist I know said the once a day dosing for liraglutide was over rated saying he has heard many people in the trials went with two shots a day to reduce side effects. He also continues to prescribe Byetta with fantastic results saying it is a life changing drug and would not have a problem prescribing LAR went it hits the market. I would be stunned if the FDA cleared liraglutide with out further study.